LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Home・Listă Acțiuni・Fate Therapeutics Inc

Fate Therapeutics Inc

Închisă

SectorSănătate

1.33 -3.62

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.28

Maxim

1.33

Indicatori cheie
By Trading Economics
Venit	1.8M -32M
Vânzări	-372K 1.4M
EPS	-0.27
Marjă de profit	-1,852.384
Angajați	181
EBITDA	-13M -42M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	+177.54% upside

Dividende
By Dow Jones
Următoarele câștiguri	11 mai 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-1.2M 173M
Deschiderea anterioară	4.95
Închiderea anterioară	1.33

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

0.9101 / 1.14 Suport & Rezistență

Fate Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 mar. 2026, 19:32 UTC

Achiziții, Fuziuni, Preluări

Diana Shipping Increases Offer to Acquire Genco -- Update

6 mar. 2026, 17:44 UTC

Achiziții, Fuziuni, Preluări

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

7 mar. 2026, 02:30 UTC

Evenimente importante

Iran War Is Kicking India When It's Already Down -- Barrons.com

6 mar. 2026, 22:26 UTC

Evenimente importante

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6 mar. 2026, 22:07 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6 mar. 2026, 22:03 UTC

Market Talk

Global Equities Roundup: Market Talk

6 mar. 2026, 22:03 UTC

Market Talk

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6 mar. 2026, 21:50 UTC

Market Talk

Evenimente importante

Financial Services Roundup: Market Talk

6 mar. 2026, 21:37 UTC

Câștiguri

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6 mar. 2026, 21:25 UTC

Evenimente importante

How The Iran War Impacts Ukraine. -- Barrons.com

6 mar. 2026, 21:17 UTC

Câștiguri

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6 mar. 2026, 20:50 UTC

Câștiguri

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6 mar. 2026, 20:46 UTC

Câștiguri

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6 mar. 2026, 20:31 UTC

Evenimente importante

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6 mar. 2026, 20:18 UTC

Market Talk

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6 mar. 2026, 20:12 UTC

Market Talk

Evenimente importante

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6 mar. 2026, 19:10 UTC

Market Talk

Evenimente importante

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6 mar. 2026, 18:54 UTC

Market Talk

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6 mar. 2026, 18:44 UTC

Market Talk

Evenimente importante

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6 mar. 2026, 18:08 UTC

Câștiguri

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mar. 2026, 18:04 UTC

Câștiguri

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mar. 2026, 18:04 UTC

Câștiguri

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mar. 2026, 17:49 UTC

Market Talk

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6 mar. 2026, 17:46 UTC

Evenimente importante

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6 mar. 2026, 17:40 UTC

Market Talk

Câștiguri

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6 mar. 2026, 17:40 UTC

Câștiguri

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mar. 2026, 17:32 UTC

Market Talk

Evenimente importante

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6 mar. 2026, 17:28 UTC

Market Talk

Evenimente importante

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6 mar. 2026, 17:20 UTC

Market Talk

Câștiguri

Auto & Transport Roundup: Market Talk

6 mar. 2026, 17:20 UTC

Market Talk

Evenimente importante

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

Fate Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

177.54% sus

Prognoză pe 12 luni

Medie 3.83 USD 177.54%

Maxim 7 USD

Minim 2 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruFate Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Fate Therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

0.9101 / 1.14Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.